Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kerry O Cleveland

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
International Journal of Antimicrobial Agents|August 21, 2022
Criteria Restricting Inappropriate Meropenem Empiricism (CRIME): a quasi-experimental carbapenem restriction pilot at a large academic medical centreDrew A Wells, Asia J Johnson, Jack G Lukas, et al.
Diagnostic Microbiology and Infectious Disease|July 2, 2019
Real-world use of telavancin in the treatment of osteomyelitisLouis D Saravolatz, Kerry O Cleveland, Khalid Rikabi, et al.
Jac-Antimicrobial Resistance|January 5, 2023
Can't keep it SECRET: system evaluation of carbapenem restriction against empirical therapyDrew A Wells, Asia J Johnson, Jack G Lukas, et al.
Jac-Antimicrobial Resistance|May 14, 2023
Assessing clinical cure of empirical piperacillin/tazobactam for ESBL urinary tract infections (ACCEPT-UTI)Sylvia S Stefanos, Sami Sakaan, Michael Samarin, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
International Journal of Antimicrobial Agents|August 21, 2022
Criteria Restricting Inappropriate Meropenem Empiricism (CRIME): a quasi-experimental carbapenem restriction pilot at a large academic medical centreDrew A Wells, Asia J Johnson, Jack G Lukas, et al.
Diagnostic Microbiology and Infectious Disease|July 2, 2019
Real-world use of telavancin in the treatment of osteomyelitisLouis D Saravolatz, Kerry O Cleveland, Khalid Rikabi, et al.
Jac-Antimicrobial Resistance|January 5, 2023
Can't keep it SECRET: system evaluation of carbapenem restriction against empirical therapyDrew A Wells, Asia J Johnson, Jack G Lukas, et al.
Jac-Antimicrobial Resistance|May 14, 2023
Assessing clinical cure of empirical piperacillin/tazobactam for ESBL urinary tract infections (ACCEPT-UTI)Sylvia S Stefanos, Sami Sakaan, Michael Samarin, et al.
Pageof 7